|
JP4976412B2
(ja)
|
2005-12-01 |
2012-07-18 |
ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー |
エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
|
|
MY150400A
(en)
|
2006-04-07 |
2014-01-15 |
Aerpio Therapeutics Inc |
Antibodies that bind human protein tyrosine phosphatase beta (hptpbeta) and uses thereof
|
|
AU2014243418B2
(en)
*
|
2010-04-30 |
2016-09-22 |
Molecular Partners Ag |
Modified binding proteins inhibiting the VEGF-A receptor interaction
|
|
TWI510246B
(zh)
|
2010-04-30 |
2015-12-01 |
Molecular Partners Ag |
抑制vegf-a受體交互作用的經修飾結合性蛋白質
|
|
CA2818969C
(en)
*
|
2010-11-26 |
2020-04-14 |
Molecular Partners Ag |
Improved n-terminal capping modules for designed ankyrin repeat proteins
|
|
AU2012249359A1
(en)
|
2011-04-29 |
2013-11-14 |
Janssen Biotech, Inc. |
IL4/IL13 binding repeat proteins and uses
|
|
WO2012172054A1
(en)
|
2011-06-16 |
2012-12-20 |
Scil Proteins Gmbh |
Modified multimeric ubiquitin proteins binding vegf-a
|
|
CN104039351A
(zh)
|
2011-10-13 |
2014-09-10 |
阿尔皮奥治疗学股份有限公司 |
用于治疗血管渗漏综合征和癌症的方法
|
|
WO2013072510A1
(en)
|
2011-11-16 |
2013-05-23 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
|
|
ES2751492T3
(es)
|
2011-11-16 |
2020-03-31 |
Adrenomed Ag |
Anticuerpo anti-adrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o armazón no Ig anti-ADM para uso en la terapia de una enfermedad aguda o una afección aguda de un paciente para estabilizar la circulación
|
|
PT2780371T
(pt)
|
2011-11-16 |
2019-01-30 |
Adrenomed Ag |
Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
|
|
CN110054690B
(zh)
|
2011-11-16 |
2023-11-24 |
艾德里诺医药公司 |
用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架
|
|
MY174877A
(en)
|
2011-11-16 |
2020-05-20 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibpdy or anti-adm antibody fragment of anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic of acute disease or acute condition
|
|
SG10202006318TA
(en)
|
2011-11-16 |
2020-08-28 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
|
|
CN103308673B
(zh)
|
2012-03-08 |
2017-05-31 |
思芬构技术有限公司 |
用于预测雌性对象中发生心血管事件的风险的方法
|
|
CN103308689B
(zh)
|
2012-03-08 |
2017-04-12 |
思芬构技术有限公司 |
用于预测雌性对象中患上癌症的风险或诊断癌症的方法
|
|
CN103308670B
(zh)
|
2012-03-08 |
2017-06-09 |
思芬构技术有限公司 |
用于预测对象患糖尿病和/或代谢综合征的风险的方法
|
|
DK2846836T3
(da)
|
2012-05-07 |
2019-11-11 |
Allergan Inc |
Fremgangsmåde til behandling af amd hos patienter, der er refraktære overfor anti-vegf-terapi
|
|
LT3777834T
(lt)
|
2012-06-01 |
2022-05-25 |
Novartis Ag |
Švirkštas
|
|
BR112014032316A2
(pt)
*
|
2012-06-28 |
2017-06-27 |
Molecular Partners Ag |
proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
|
|
AU2013100070B4
(en)
*
|
2012-07-03 |
2013-04-04 |
Novartis Ag |
Use of device
|
|
AU2012101677B4
(en)
*
|
2012-07-03 |
2012-12-20 |
Novartis Ag |
Device
|
|
JOP20200175A1
(ar)
|
2012-07-03 |
2017-06-16 |
Novartis Ag |
حقنة
|
|
WO2014033184A1
(en)
*
|
2012-08-28 |
2014-03-06 |
Novartis Ag |
Use of a vegf antagonist in treating ocular vascular proliferative diseases
|
|
RU2707303C1
(ru)
|
2012-10-02 |
2019-11-26 |
Сфинготек Гмбх |
Способ диагностики или мониторинга почечной функции или диагностики почечной дисфункции
|
|
EP2738180A1
(en)
|
2012-11-30 |
2014-06-04 |
Molecular Partners AG |
Binding proteins comprising at least two binding domains against HER2.
|
|
CA2897327A1
(en)
|
2013-01-08 |
2014-07-17 |
Sphingotec Gmbh |
Fasting levels of growth hormone as a predictive marker of cardiovascular risk
|
|
CN105143270B
(zh)
*
|
2013-02-26 |
2019-11-12 |
罗切格利卡特公司 |
双特异性t细胞活化抗原结合分子
|
|
JP6649246B2
(ja)
*
|
2013-03-14 |
2020-02-19 |
アラーガン、インコーポレイテッドAllergan,Incorporated |
タンパク質の徐放性送達の組成物及び製造プロセス中のタンパク質の安定化方法
|
|
ES2830036T3
(es)
|
2013-03-20 |
2021-06-02 |
Sphingotec Gmbh |
Adrenomedulina para guiar una terapia de disminución de la presión sanguínea
|
|
FR3004650B1
(fr)
*
|
2013-04-22 |
2015-05-29 |
Affilogic |
Composition topique comprenant un variant d'une protéine sauvage à pli-OB, ainsi que son procédé de préparation
|
|
CN105209483B
(zh)
|
2013-05-31 |
2021-07-27 |
分子组合公司 |
与肝细胞生长因子结合的设计锚蛋白重复蛋白
|
|
WO2014203182A1
(en)
|
2013-06-20 |
2014-12-24 |
Novartis Ag |
Use of a vegf antagonist in treating choroidal neovascularisation
|
|
US20160129080A1
(en)
|
2013-06-20 |
2016-05-12 |
Aaron Osborne |
Treatment of polypoidal chroidal vasculopathy
|
|
EP3010526A1
(en)
|
2013-06-20 |
2016-04-27 |
Novartis AG |
Use of a vegf antagonist in treating macular edema
|
|
WO2015004616A1
(en)
|
2013-07-11 |
2015-01-15 |
Novartis Ag |
Use of a vegf antagonist in treating chorioretinal neovascular and permeability disorders in paediatric patients
|
|
JP2016523956A
(ja)
|
2013-07-11 |
2016-08-12 |
ノバルティス アーゲー |
未熟児網膜症の治療におけるvegfアンタゴニストの使用
|
|
SG10201708882TA
(en)
|
2013-07-12 |
2017-12-28 |
Ophthotech Corp |
Methods for treating or preventing ophthalmological conditions
|
|
DK3065761T3
(da)
*
|
2013-11-05 |
2020-02-17 |
Allergan Inc |
Fremgangsmåde til behandling af tilstande af øjet med en anti-vegf darpin
|
|
US20170232199A1
(en)
|
2014-05-12 |
2017-08-17 |
Formycon Ag |
Pre-Filled Plastic Syringe Containing a VEGF Antagonist
|
|
EP3002589A1
(en)
|
2014-10-01 |
2016-04-06 |
sphingotec GmbH |
A method for stratifying a female subject for hormone replacement therapy
|
|
EP3277711B9
(en)
|
2015-04-02 |
2023-08-16 |
Molecular Partners AG |
Designed ankyrin repeat domains with binding specificity for serum albumin
|
|
SG11201708655UA
(en)
|
2015-04-24 |
2017-11-29 |
Sphingotec Gmbh |
A method for predicting the risk of incidence of chronic kidney disease
|
|
TWI799366B
(zh)
|
2015-09-15 |
2023-04-21 |
美商建南德克公司 |
胱胺酸結骨架平臺
|
|
CA3005132A1
(en)
|
2015-11-18 |
2017-05-26 |
Sio2 Medical Products, Inc. |
Coated syringe for ophthalmic formulations containing a vegf antagonist
|
|
KR20180083377A
(ko)
|
2015-11-18 |
2018-07-20 |
포르미콘 아게 |
Vegf 안타고니스트를 함유하는 사전충전형 플라스틱 주사기
|
|
CA3005117C
(en)
|
2015-11-18 |
2023-01-24 |
Formycon Ag |
Pre-filled pharmaceutical package comprising a liquid formulation of a vegf-antagonist
|
|
AU2017213103B2
(en)
|
2016-01-26 |
2022-08-11 |
Formycon Ag |
Liquid formulation of a VEGF antagonist
|
|
CN109073660B
(zh)
|
2016-02-29 |
2022-10-28 |
麦恩泰科特有限公司 |
可用于治疗湿性年龄相关性黄斑变性的预测性标志物
|
|
KR102886883B1
(ko)
|
2016-04-21 |
2025-11-19 |
4틴4 파마슈티컬스 게엠베하 |
Dpp3을 결정하는 방법 및 치료 방법
|
|
MA45493A
(fr)
|
2016-06-27 |
2019-05-01 |
Aicuris Anti Infective Cures Gmbh |
Inhibiteurs d'entrée de hcmv.
|
|
CN109716136B
(zh)
|
2016-07-08 |
2023-09-22 |
斯弗因高泰克有限公司 |
肾上腺髓质素用于评估急性心力衰竭患者的充血
|
|
WO2018017714A1
(en)
|
2016-07-20 |
2018-01-25 |
Aerpio Therapeutics, Inc. |
HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß)
|
|
AU2017331329B2
(en)
|
2016-09-22 |
2020-10-29 |
Molecular Partners Ag |
Recombinant binding proteins and their use
|
|
EP3309550A1
(en)
|
2016-10-12 |
2018-04-18 |
sphingotec GmbH |
Method for the detection of apolipoprotein e4
|
|
AU2017375049B2
(en)
|
2016-12-16 |
2025-01-30 |
Adrenomed Ag |
Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
|
EP3339324A1
(en)
|
2016-12-22 |
2018-06-27 |
sphingotec GmbH |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
|
|
EP3630062A2
(en)
|
2017-05-24 |
2020-04-08 |
SiO2 Medical Products, Inc. |
Sterilizable pharmaceutical package for ophthalmic formulations
|
|
WO2018215580A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Method for sterilizing prefilled plastic syringes containing a vegf antagonist
|
|
WO2018217995A1
(en)
|
2017-05-24 |
2018-11-29 |
Formycon Ag |
Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
|
|
MX2019014441A
(es)
|
2017-05-30 |
2020-02-10 |
Sphingotec Gmbh |
Un metodo in vitro para diagnosticar o monitorear la funcion renal o diagnosticar disfuncion renal.
|
|
TW201904610A
(zh)
|
2017-06-14 |
2019-02-01 |
德商拜耳製藥公司 |
用於治療新生血管型青光眼之非抗體vegf拮抗劑
|
|
WO2019020777A1
(en)
|
2017-07-26 |
2019-01-31 |
Formycon Ag |
LIQUID FORMULATION OF A VEGF ANTAGONIST
|
|
CA3073125A1
(en)
|
2017-08-18 |
2019-02-21 |
Cambridge Enterprise Limited |
Modular binding proteins
|
|
CA3076691A1
(en)
|
2017-09-25 |
2019-03-28 |
Adrenomed Ag |
Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness
|
|
SG11202002268XA
(en)
|
2017-10-18 |
2020-04-29 |
Adrenomed Ag |
Therapy monitoring under treatment with an anti-adrenomedullin (adm) binder
|
|
CN111542755A
(zh)
|
2017-10-24 |
2020-08-14 |
思芬构技术有限公司 |
用于预测第一次心血管事件的硒蛋白p
|
|
MX2020004271A
(es)
|
2017-10-25 |
2020-07-29 |
4TEEN4 Pharmaceuticals GmbH |
Aglutinante de dpp3 dirigido a y que se une a epitopes de dpp3 especificos y su uso en la prevencion o tratamiento de enfermedades/condiciones agudas que estan asociadas con estres oxidativo.
|
|
MX421834B
(es)
|
2018-02-08 |
2025-03-14 |
Sphingotec Gmbh |
Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia
|
|
EP3569614A1
(en)
|
2018-05-18 |
2019-11-20 |
Julius-Maximilians-Universität Würzburg |
Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase
|
|
EP3586865A1
(en)
|
2018-06-21 |
2020-01-01 |
Charité - Universitätsmedizin Berlin |
Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis
|
|
EP3856245A4
(en)
|
2018-09-24 |
2022-10-26 |
EyePoint Pharmaceuticals, Inc. |
MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
|
|
MX2021007467A
(es)
|
2018-12-20 |
2021-08-05 |
Sphingotec Gmbh |
Selenoproteina p en insuficiencia cardiaca.
|
|
JP2022516438A
(ja)
|
2018-12-21 |
2022-02-28 |
4ティーン4 ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
アンジオテンシン受容体アゴニストおよび/またはその前駆体による治療のための治療ガイドおよび/または治療モニタリング
|
|
SG11202112921VA
(en)
|
2019-06-04 |
2021-12-30 |
Molecular Partners Ag |
Multispecific proteins
|
|
US20220291234A1
(en)
|
2019-08-15 |
2022-09-15 |
Sphingotec Gmbh |
A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction in pediatric patients
|
|
EP4021571B1
(en)
|
2019-08-30 |
2025-10-08 |
4TEEN4 Pharmaceuticals GmbH |
Therapy guidance and/or therapy monitoring for treatment of shock
|
|
CA3161321A1
(en)
|
2019-12-11 |
2021-06-17 |
Victor LEVITSKY |
Recombinant peptide-mhc complex binding proteins and their generation and use
|
|
EP3871689A1
(en)
|
2020-02-26 |
2021-09-01 |
sphingotec GmbH |
Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
|
|
CN115244081A
(zh)
|
2020-02-27 |
2022-10-25 |
艾德里诺医药公司 |
用于治疗休克患者的抗肾上腺髓质素(adm)结合剂
|
|
WO2021170876A1
(en)
|
2020-02-27 |
2021-09-02 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
|
BR112022015215A2
(pt)
|
2020-02-27 |
2022-10-11 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 para orientação, monitoramento e estratificação de terapia de anticorpos nt-adm em pacientes com choque
|
|
MX2022011581A
(es)
|
2020-03-16 |
2022-10-18 |
Adrenomed Ag |
Proadrenomedulina o fragmento de la misma en pacientes infectados con coronavirus y tratamientos con aglutinante contra la adrenomedulina.
|
|
US20230213519A1
(en)
|
2020-03-16 |
2023-07-06 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
EP3922993A1
(en)
|
2020-06-12 |
2021-12-15 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 in patients infected with coronavirus
|
|
WO2021224686A1
(en)
|
2020-05-06 |
2021-11-11 |
Molecular Partners Ag |
Novel ankyrin repeat binding proteins and their uses
|
|
CA3178785A1
(en)
|
2020-05-14 |
2021-11-18 |
Nicolo RIGAMONTI |
Multispecific proteins
|
|
EP4023218A1
(en)
|
2020-12-02 |
2022-07-06 |
S-Form Pharma |
Combination therapy for patients having acute and/or persistent dyspnea
|
|
CA3202358A1
(en)
|
2020-12-16 |
2022-06-23 |
Andreas BOSSHART |
Novel slow-release prodrugs
|
|
WO2022190016A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based multi-specific t-cell engagers
|
|
JP2024509890A
(ja)
|
2021-03-09 |
2024-03-05 |
モレキュラー パートナーズ アクチェンゲゼルシャフト |
プロテアーゼ切断可能なプロドラッグ
|
|
AU2022233791A1
(en)
|
2021-03-09 |
2023-09-28 |
Molecular Partners Ag |
Novel darpin based cd123 engagers
|
|
WO2022190010A1
(en)
|
2021-03-09 |
2022-09-15 |
Molecular Partners Ag |
Novel darpin based cd33 engagers
|
|
BR112023022439A2
(pt)
|
2021-04-26 |
2023-12-26 |
Celanese Eva Performance Polymers Llc |
Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
|
|
JP2024526081A
(ja)
|
2021-06-18 |
2024-07-17 |
シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング |
敗血症及び敗血症性ショックを予測する方法
|
|
KR20240041912A
(ko)
|
2021-06-29 |
2024-04-01 |
베리솔 게엠베하 |
체액내 셀레늄 결핍을 식별하기 위한 복합 바이오마커
|
|
EP4145456A1
(en)
|
2021-09-06 |
2023-03-08 |
Bayer AG |
Prediction of a change related to a macular fluid
|
|
KR20240122764A
(ko)
|
2021-12-14 |
2024-08-13 |
몰리큘라 파트너스 아게 |
이중 결합 특이성을 갖는 설계된 반복 도메인과 이의 용도
|
|
CN119072492A
(zh)
|
2022-03-15 |
2024-12-03 |
艾德里诺医药公司 |
抗肾上腺髓质素(adm)抗体或抗adm抗体片段的稳定水性制剂
|
|
WO2024023369A1
(en)
|
2022-07-29 |
2024-02-01 |
Adrenomed Ag |
Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
|
|
AU2023315168A1
(en)
|
2022-07-29 |
2025-02-13 |
4TEEN4 Pharmaceuticals GmbH |
Prediction of an increase of dpp3 in a patient with septic shock
|
|
CN119731200A
(zh)
|
2022-08-01 |
2025-03-28 |
分子合作伙伴股份公司 |
经电荷修饰设计的重复结构域及其用途
|
|
WO2024038307A1
(en)
|
2022-08-19 |
2024-02-22 |
Novartis Ag |
Dosing regimens for sars-cov-2 binding molecules
|
|
WO2024059686A2
(en)
*
|
2022-09-15 |
2024-03-21 |
The Regents Of The University Of California |
Darpin backbones and rigidified electron microscopy imaging scaffolds
|
|
WO2024126793A1
(en)
|
2022-12-15 |
2024-06-20 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
|
|
WO2024179981A1
(en)
|
2023-02-27 |
2024-09-06 |
Molecular Partners Ag |
Darpins for use in reducing renal accumulation of drugs
|
|
CN120731367A
(zh)
|
2023-03-17 |
2025-09-30 |
Pam治疗诊断有限公司 |
肽基甘氨酸α-酰胺化单加氧酶(PAM)的测定方法及其诊断用途
|
|
WO2024200862A1
(en)
|
2023-03-29 |
2024-10-03 |
4TEEN4 Pharmaceuticals GmbH |
Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline
|
|
WO2025068313A1
(en)
|
2023-09-25 |
2025-04-03 |
Sphingotec Gmbh |
A method for early diagnosis, early prediction, monitoring or prediction of severity of reduced graft function in a kidney transplantation patient
|
|
WO2025146491A1
(en)
|
2024-01-05 |
2025-07-10 |
Molecular Partners Ag |
Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
|
|
WO2025229075A1
(en)
|
2024-05-03 |
2025-11-06 |
Sphingotec Gmbh |
A method for the specific determination of proenkephalin fragment 119-159
|
|
WO2025248139A1
(en)
|
2024-05-31 |
2025-12-04 |
4TEEN4 Pharmaceuticals GmbH |
Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
|
|
EP4675277A1
(en)
|
2024-07-05 |
2026-01-07 |
Predemtec AG |
A method for diagnosing alzheimer´s disease or determining the risk of suffering from alzheimer´s disease
|